Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma